Advertisement

Pharmacologic Goals in Interstitial Cystitis/Bladder Pain Syndrome

  • Antonella Giannantoni
  • Marilena Gubbiotti
  • Naoki Yoshimura
  • Karl-Erik Andersson
Chapter

Abstract

During the last 30 years, a number of treatments and management algorithms have been developed and applied in the treatment of patients with Interstitial Cystitis/Bladder Painful Syndrome (IC/BPS), and many behavioral, dietary, interventional, pharmacologic and surgical therapies have been developed in the attempt to control the disease and to offer substantial benefits to the affected patients. Nevertheless, the complexity of the disease in terms of aetiology and pathogenesis still has made it difficult to induce significant and long-lasting benefits for any kind of these treatments. In addition, few well designed, randomised controlled trials have been conducted until now on different treatment modalities, and this still precludes the development of evidence-based management strategies. Indeed, the majority of pharmacological agents used to treat patients with IC/BPS are still off label. In this respect, the Interstitial Cystitis Data Base study noted >180 treatment modalities for IC/BPS, with poor results in the majority of cases [1]. To date, there is general agreement on the use of some agents, orally or intravesically administered, as indicated by the EAU guidelines on chronic pelvic pain [2] and the AUA Guidelines for the Diagnosis and Treatment of Interstitial Cystitis/ Bladder Pain Syndrome [3].

References

  1. 1.
    Rovner E, Propert KJ, Brensinger C, Wein AJ, Foy M, Kirkemo A, Landis JR, Kusek JW, Nyberg LM. Treatments used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology. 2000;56(6):940–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Engeler DS, Baranowski AP, Dinis-Oliveira P, Elneil S, Hughes J, Messelink EJ, van Ophoven A, Williams AC, European Association of Urology. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol. 2013;64:431–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, Newman D, Nyberg L Jr, Payne CK, Wesselmann U, Faraday MM, Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185:2162–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S, Wyndaele JJ. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61:29–53.CrossRefPubMedGoogle Scholar
  5. 5.
    Davis NF, Brady CM, Creagh T. Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Biol. 2014;175:30–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Pazin C, Moreira de Souza Mitidieri A, Moreira Silva AP, Ferreira Gurian MB, Poli-Neto OB, Rosa-e-Silva JC. Treatment of bladder pain syndrome and interstitial cystitis: a systematic review. Int Urogynecol J. 2016;27:697–708.CrossRefPubMedGoogle Scholar
  7. 7.
    van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Ogawa T, Ishizuka O, Ueda T, Tyagi P, Chancellor MB, Yoshimura N. Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). Expert Opin Emerg Drugs. 2015;20(4):555–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Fall M, Logadottir Y, Peeker R. Interstitial cystitis is bladder pain syndrome with Hunner’s lesion. Int J Urol. 2014;21(Suppl 1):79–82.CrossRefPubMedGoogle Scholar
  10. 10.
    Nickel JC, Irvine-Bird K, Jianbo L, et al. Phenotype-directed management of interstitial cystitis/bladder pain syndrome. Urology. 2014 Jul;84(1):175–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Hurst RE. Structure, function and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol. 1994;12:3–10.CrossRefPubMedGoogle Scholar
  12. 12.
    Emtage J, Morales A, Heaton JPW, Perez-Marrero R. Heparin in the treatment of interstitial cystitis. J Urol. 1985;133:168.Google Scholar
  13. 13.
    Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol. 1996;156:45–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Bade JJ, Laseur M, Nieuwenburg LT, van der Weele LT, Mensink HJ. A placebo-controlled study of intravesical Pentosanpolysulfate for the treatment of interstitial cystitis. Br J Urol. 1997;79:168–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Parsons CL, Schmidt JD, Pollen JJ. Successful treatment of interstitial cystitis with sodium pentosan polysulfate. J Urol. 1983;130:51–3.CrossRefPubMedGoogle Scholar
  16. 16.
    Hanno PM. Analysis of long-term Elmiron therapy for interstitial cystitis. Urology. 1997;49(5A Suppl):93–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Jepsen JV, Sall M, Rhodes PR, Schmidt D, Messing E, Bruskewitz RC. Long term experience with pentosanpolysulfate in interstitial cystitis. Urology. 1998;51:381–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Nickel JC, Kaufman DM, Zhang HF, Wan GJ, Sand PK. Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement. Urology. 2008;71:57–61.CrossRefPubMedGoogle Scholar
  19. 19.
    Sand PK, Kaufman DM, Evans RJ, Zhang HF, Alan Fisher DL, Nickel JC. Association between response to pentosan polysulfate sodium therapy for interstitial cystitis and patient questionnaire-based treatment satisfaction. Curr Med Res Opin. 2008;24:2259–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Chuang YC, Lee WC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009;182:1393–400.CrossRefPubMedGoogle Scholar
  21. 21.
    Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol. 1993;150:845–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170:810–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005;65:654–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Sairanen J, Tammela TLJ, Leppilahti M, et al. Cyclosporine A and pentosanpolysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005;174:2235–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol. 2008;179:177–85.CrossRefPubMedGoogle Scholar
  26. 26.
    Sorensen RB. Chondroitin sulphate in the treatment of interstitial cystitis and chronic inflammatory disease of the urinary bladder. Eur Urol Suppl. 2003;2(4):16–8.CrossRefGoogle Scholar
  27. 27.
    Steinhoff G. The efficacy of chondroitin sulphate in treating interstitial cystitis. Eur Urol Suppl. 2003;14-16(10):2.Google Scholar
  28. 28.
    Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, Irvine-Bird K. A real-life multi-centre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulfate for the treatment of interstitial cystitis. BJU Int 2008;103:56–6.Google Scholar
  29. 29.
    Nordling J, van Ophoven A. Intravesical Glysosaminoglycan replenishment with chondroitin sulfate in chronic forms of cystitis. Arzneimittelforschung. 2008;58:328–35.PubMedGoogle Scholar
  30. 30.
    Nickel JC, Egerdie RB, Steinhoff G, Palmer B, Hanno P. A multicenter, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome. Urology. 2010;76:804–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pflüger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:717–21.CrossRefPubMedGoogle Scholar
  32. 32.
    Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pflüger H. Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol. 2005;47:393–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Shao Y, Shen ZJ, RuiWB ZWL. Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. J Urol. 2010;75:547–50.CrossRefGoogle Scholar
  34. 34.
    Thilagarajah R, Witherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int. 2001;87:207–12.CrossRefPubMedGoogle Scholar
  35. 35.
    van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study ofamitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172:533–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Foster HE, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/ painful bladder syndrome. J Urol. 2010;183:1853–8.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    van Ophoven A, Hertle L. The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study. J Urol. 2007;177:552–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc. 2004;36(2 Suppl):25S–32S.CrossRefPubMedGoogle Scholar
  39. 39.
    Moran PA, Dwyer PL, Carey MP, Maher CF, Radford NJ. Oral methotrexate in the management of refractory interstitial cystitis. Aust N Z J Obstet Gynaecol. 1999;39(4):468–71.CrossRefPubMedGoogle Scholar
  40. 40.
    Ueda T, Tamaki M, Ogawa O, Yamauchi T, Yoshimura N. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T. J Urol. 2000;164:1917–20.CrossRefPubMedGoogle Scholar
  41. 41.
    Ochodnicky P, Cruz CD, Yoshimura N, Cruz F. Neurotrophins as regulators of urinary bladder function. Nat Rev Urol. 2012;9(11):628–37.PubMedGoogle Scholar
  42. 42.
    Lowe EM, Anand P, Terenghi G, et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997;79(4):572–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Okragly AJ, Niles AL, Saban R, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol. 1999;161(2):438–41. discussion 41-2CrossRefPubMedGoogle Scholar
  44. 44.
    HC Q, Zhang W, Yan S, et al. Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis. PLoS One. 2014;9(9):e106321.CrossRefGoogle Scholar
  45. 45.
    Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716–21.CrossRefPubMedGoogle Scholar
  46. 46.
    Wang H, Russell LJ, Kelly KM, Wang S, Thipphawong J. Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study. BMC Urol. 2017;17(1):2.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Tyagi P, Kashyap M, Majima T, Kawamorita N, Yoshizawa T, Yoshimura N. Intravesical liposome therapy for interstitial cystitis. Int J Urol. 2017;24(4):267–71.CrossRefGoogle Scholar
  48. 48.
    Henry RA, Morales A, Cahill CM. Beyond a simple anesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Urology. 2015;85(5):1025–33.CrossRefPubMedGoogle Scholar
  49. 49.
    Nickel JC, Moldwin R, Lee S, et al. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103(7):910–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):143ra00.CrossRefGoogle Scholar
  51. 51.
    Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407(6807):1011–5.CrossRefPubMedGoogle Scholar
  52. 52.
    Sun Y, Chai TC. Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis. BJU Int. 2002;90(4):381–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Sun Y, Keay S, De Deyne PG, et al. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol. 2001;166(5):1951–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Sun Y, Chai TC. Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J Urol. 2004;171(1):448–52.CrossRefPubMedGoogle Scholar
  55. 55.
    Sun Y, Chai TC. Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis. Am J Physiol Cell Physiol. 2006;290(1):C27–34.CrossRefPubMedGoogle Scholar
  56. 56.
    Moldwin R, Kitt M, Mangel J, Beyer R, Hanno P, Butera P, Ford A. A phase 2 study in women with interstitial cystitis/bladder pain syndrome (IC/BPS) of the novel P2X3 antagonist AF-219 (Abstract #23), 45th International Continence Society (ICS) Annual Meeting, Montreal, Canada, 2015.Google Scholar
  57. 57.
    Stenton GR, Mackenzie LF, Tam P, et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol. 2013;168(6):1506–18.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Nickel JC, Egerdie B, Davis E, Evans R, Mackenzie L, Shrewsbury SB. A phase II study of the efficacy and safety of the novel oral SHIP1 activator AQX-1125 in subjects with moderate to severe interstitial cystitis/bladder pain syndrome. J Urol. 2016;196(3):747–54.CrossRefPubMedGoogle Scholar
  59. 59.
    Ogawa T, Homma T, Igawa Y, et al. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol. 2010;183(3):1206–12.CrossRefPubMedGoogle Scholar
  60. 60.
    Fall M, Johansson SL, Aldenborg F. Chronic interstitial cystitis: a heterogeneous syndrome. J Urol. 1987;137(1):35–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Killinger KA, Boura JA, Peters KM. Pain in interstitial cystitis/bladder pain syndrome: do characteristics differ in ulcerative and non-ulcerative subtypes? Int Urogynecol J. 2013;24(8):1295–301.CrossRefPubMedGoogle Scholar
  62. 62.
    Fall M, Baranowski AP, Elneil S, et al. EAU guidelines on chronic pelvic pain. Eur Urol. 2010;57(1):35–48.CrossRefPubMedGoogle Scholar
  63. 63.
    Logadottir Y, Fall M, Kabjorn-Gustafsson C, et al. Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol. 2012;46(5):365–70.CrossRefPubMedGoogle Scholar
  64. 64.
    Wennevik GE, Meijlink JM, Hanno P, Nordling J. The role of glomerulations in bladder pain syndrome: a review. J Urol. 2016;195(1):19–25.CrossRefPubMedGoogle Scholar
  65. 65.
    Ueda T, Nakagawa M, Okamura M, et al. New cystoscopic diagnosis for interstitial cystitis/painful bladder syndrome using narrow-band imaging system. Int J Urol. 2008;15(12):1039–43.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Antonella Giannantoni
    • 1
  • Marilena Gubbiotti
    • 1
  • Naoki Yoshimura
    • 2
  • Karl-Erik Andersson
    • 3
  1. 1.Urology Section, Department of Surgical and Biomedical SciencesUniversity of PerugiaPerugiaItaly
  2. 2.Department of Urology, School of MedicineUniversity of PittsburghPittsburghUSA
  3. 3.Institute for Regenerative Medicine, Wake Forest University School of MedicineWinston SalemUSA

Personalised recommendations